FOLH1 and neoplasm: Late images beyond 20 h after injection demonstrated prolonged trapping in tumor lesions, additional hepatobiliary clearance into the intestine, and low residual uptake in other organs (Fig. 5B); thus, to some degree, PSMA-GCK01 has tumor accumulation and excretion kinetics similar to those of other Glu-urea–based PSMA ligands, such as MIP-1095, PSMA-617, or PSMA-I&T (20–22).